Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Solomon, Scott
Item TypeName
Academic Article Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Academic Article Aldosterone antagonism and myocardial infarction: from animals to man and back.
Academic Article Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist.
Academic Article Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
Academic Article Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.
Academic Article Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
Concept Receptors, Mineralocorticoid
Academic Article Race influences the safety and efficacy of spironolactone in severe heart failure.
Academic Article Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Academic Article Spironolactone for heart failure with preserved ejection fraction.
Academic Article Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
Academic Article Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Academic Article Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
Academic Article New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Academic Article Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Academic Article Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial.
Academic Article Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Academic Article Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Academic Article Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Academic Article Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Academic Article QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
Academic Article Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Academic Article Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.
Academic Article Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Academic Article Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Academic Article Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.
Academic Article Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist).
Academic Article Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
Academic Article Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
Academic Article Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Academic Article Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
Academic Article Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
Academic Article Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Academic Article Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
Academic Article The frailty syndrome and outcomes in the TOPCAT trial.
Academic Article Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.
Academic Article Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Academic Article Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction.
Academic Article Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Academic Article Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Academic Article Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction.
Academic Article Application of the H2 FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial.
Academic Article Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Academic Article Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial.
Academic Article Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Academic Article Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
Academic Article Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
Academic Article Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Academic Article Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT.
Academic Article Associations Between Depressive Symptoms and HFpEF-Related Outcomes.
Academic Article Estimating the Lifetime Benefits of Treatments for Heart Failure.
Academic Article Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Academic Article Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial.
Academic Article Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
Academic Article Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Search Criteria
  • Receptors Mineralocorticoid
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.